Time limited offer for new users ▶ Get up to 3 months free

Serving leading biopharmaceutical companies globally:

Baxter
AstraZeneca
McKesson
Harvard Business School
McKinsey
Moodys

Last Updated: January 27, 2023

CLINICAL TRIALS PROFILE FOR DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%


✉ Email this page to a colleague

« Back to Dashboard

▶ Start for $1
Remove trial restrictions


All Clinical Trials for Diltiazem Hydrochloride In Dextrose 5%

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00000478 ↗ Asymptomatic Cardiac Ischemia Pilot (ACIP) Study Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1990-11-01 To assess the feasibility of and test the methodology for a full-scale clinical trial of therapies for asymptomatic cardiac ischemia.
NCT00000556 ↗ Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) Completed National Heart, Lung, and Blood Institute (NHLBI) Phase 3 1995-03-01 To compare two standard treatment strategies for atrial fibrillation: ventricular rate control and anticoagulation vs. rhythm control and anticoagulation.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed US Department of Veterans Affairs 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
NCT00007592 ↗ Hypertension Screening and Treatment Program Completed VA Office of Research and Development 1989-06-01 Hypertension is one of the most common medical problems in the United States and in the VA health care system. It has been well-documented that hypertension can be effectively treated. However, there remain important unresolved clinical questions in the area of antihypertensive treatment. For example, how much is mortality affected by visit compliance, blood pressure control and type of antihypertensive agent? Or, are some regimens associated with more morbidity than others? Or, are there inexpensive regimens that are as effective as more expensive regimens? The amount of data that is available from this demonstration project (currently 6,100 patients) will help address these questions. The answers to these questions should result in better care for veterans with hypertension.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Diltiazem Hydrochloride In Dextrose 5%

Condition Name

Condition Name for Diltiazem Hydrochloride In Dextrose 5%
Intervention Trials
Atrial Fibrillation 12
Hypertension 10
Healthy Subjects 5
Heart Failure 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for Diltiazem Hydrochloride In Dextrose 5%
Intervention Trials
Atrial Fibrillation 16
Hypertension 9
Fissure in Ano 8
Atrial Flutter 6
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for Diltiazem Hydrochloride In Dextrose 5%

Trials by Country

Trials by Country for Diltiazem Hydrochloride In Dextrose 5%
Location Trials
United States 149
Mexico 9
Australia 8
Germany 7
France 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for Diltiazem Hydrochloride In Dextrose 5%
Location Trials
California 10
Texas 7
New York 7
North Carolina 6
Tennessee 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for Diltiazem Hydrochloride In Dextrose 5%

Clinical Trial Phase

Clinical Trial Phase for Diltiazem Hydrochloride In Dextrose 5%
Clinical Trial Phase Trials
Phase 4 25
Phase 3 14
Phase 2/Phase 3 3
[disabled in preview] 11
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for Diltiazem Hydrochloride In Dextrose 5%
Clinical Trial Phase Trials
Completed 58
Unknown status 16
Recruiting 14
[disabled in preview] 6
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for Diltiazem Hydrochloride In Dextrose 5%

Sponsor Name

Sponsor Name for Diltiazem Hydrochloride In Dextrose 5%
Sponsor Trials
VA Office of Research and Development 5
Ventrus Biosciences, Inc 5
AstraZeneca 4
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for Diltiazem Hydrochloride In Dextrose 5%
Sponsor Trials
Other 98
Industry 39
U.S. Fed 13
[disabled in preview] 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
McKesson
Boehringer Ingelheim
AstraZeneca
Moodys
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.